Merck Sharp & Dohme Corp. v. Zydus Pharmaceuticals (USA) Inc. et al.

I'll research this case thoroughly using web search.

Let me dig deeper into the specifics: the accused product, the IPRs, the MDL, and the settlement.

Case Overview: Merck Sharp & Dohme Corp. v. Zydus Pharmaceuticals (USA) Inc., No. 1:19-cv-00314-RGA (D. Del.)

Parties and the accused product. The plaintiff is Merck Sharp & Dohme Corp. (MSD), a wholly owned subsidiary and patent-holding arm of Merck & Co., Inc. — an operating innovator pharmaceutical company, not an NPE, university, or PAE (D.I. 5, Rule 7.1 disclosure; Merck is identified as "owner and assignee" of the '708 patent in IPR2020-00040 mandatory notices). The defendants are Zydus Pharmaceuticals (USA) Inc., the U.S. marketing subsidiary registered in Delaware and New Jersey, and its Indian parent Cadila Healthcare Ltd. (now Zydus Lifesciences Ltd.) — one of the largest Indian generics manufacturers (D.I. 12–13 disclosure statements). The suit is a Hatch-Waxman action: Merck alleged that Zydus's regulatory submission for a generic sitagliptin product infringed under 35 U.S.C. § 271(e)(2). The docket form lists a Paragraph IV notice date of 5/29/2015 and an expiration date for the patent of 11/24/2026 (D.I. 3), although the 2015 notice date is difficult to reconcile with a 2019 complaint and I have not verified it independently. The commercial target was Januvia (sitagliptin phosphate), Janumet, Janumet XR, and Juvisync (Orange Book listing: '708 expires Nov. 24, 2026, with pediatric exclusivity to May 24, 2027). Notably, Zydus ultimately pivoted away from a plain generic: on Oct. 31/Nov. 2, 2020 it filed a 505(b)(2) NDA (No. 211566) for sitagliptin free base (amorphous) tablets — a different form of the active moiety than Merck's sitagliptin phosphate monohydrate — receiving tentative approval Sept. 2, 2021, a Complete Response Letter in March 2023, and final approval Oct. 18, 2023 as Zituvio. Zydus's own U.S. Patent 10,925,871 claims a malic-acid-stabilized amorphous sitagliptin free-base composition (FDA NDA 211566 administrative correspondence; Drugs@FDA). That product is "non-automatically substitutable" — it carries no therapeutic-equivalence code, so it competes as a branded product rather than as a pharmacy-level generic substitute.

The patent and procedural posture. Only one patent is asserted here: U.S. Patent No. 7,326,708, "Phosphoric Acid Salt of a Dipeptidyl Peptidase-IV Inhibitor" (filed June 23, 2004; issued Feb. 5, 2008; inventors Cypes, Chen, Ferlita, Hansen, Lee, Vydra, and Wenslow). In one line: it claims the 1:1 dihydrogenphosphate (DHP) salt of sitagliptin — i.e., the specific phosphate salt form of Merck's DPP-4 inhibitor 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine — plus hydrates (claims 1–3), the crystalline monohydrate (claims 4–16), pharmaceutical compositions (claim 17), methods of treating Type 2 diabetes (claim 19), and process claims (claims 21–24). The companion patent in Merck's campaign, U.S. 8,414,921 (sitagliptin + metformin compositions), was asserted against some defendant groups but not against Zydus in this action (D.I. 4 lists only 7,326,708; JPML order, MDL 2902). This case was filed Feb. 13, 2019 in the District of Delaware, assigned to Judge Richard G. Andrews, as one of fourteen parallel suits Merck filed that season (thirteen in D. Del.; one against Mylan in the N.D. W. Va.). On the JPML's July 2019 transfer order, the actions were centralized as In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation, MDL No. 19-2902, before Judge Andrews in Delaware, and the court issued a consolidated claim construction opinion on Nov. 17, 2020 (D.I. 135 in 19-cv-00311). Venue matters here because Delaware is the dominant Hatch-Waxman forum and the JPML expressly selected it (13 of 14 actions were already there) to avoid inconsistent claim-construction and validity rulings across 26 ANDAs. The case is recorded as settled in December 2022; Merck's SEC filings describe a December 2022 settlement that dismissed the Zydus sitagliptin action without prejudice, "enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Januvia." One caveat I flag rather than paper over: Merck's 10-Q/10-K disclosures attribute that December 2022 resolution to the suit over Zydus's 505(b)(2) NDA (a case Merck says it filed in March 2021 against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd.), while the caption given to me is the 2019 ANDA action — the two Zydus threads appear related but distinct, and I could not verify from the sources retrieved which docket entry closed 1:19-cv-00314.

Why it is notable. Four things stand out. (1) Life-cycle/evergreening positioning: the '708 salt/polymorph patent runs years past the sitagliptin compound patent (U.S. 6,699,871, expired Jan. 26, 2023) and the '873 patent, extending Januvia-family exclusivity into 2026–2027 — a textbook example of secondary-patent life-cycle management that generic challengers attacked as obvious over Merck's own earlier WO 03/004498 application. (2) IPR linkage: Mylan's IPR2020-00040 (filed Oct. 30, 2019; instituted May 12, 2020) went to a final written decision on May 7, 2021 (oral hearing Feb. 11, 2021) in which the Board held Mylan had not proven claims 1–4, 17, 19, and 21 unpatentable — rejecting inherent-anticipation "closed list" and inherency theories on chemical salt formation, and addressing Merck's prior reduction to practice and common-ownership (§ 102(a)/§ 103(c)(1)) arguments (PTAB FWD; Finnegan commentary, Sept. 21, 2021). Follow-on petitions by Sun Pharmaceutical, Dr. Reddy's, and Teva (IPR2020-01045, -01060, and related) were filed in mid-2020, with PTAB decision dates around Sept. 1, 2020; I did not verify each outcome and will not assert them. A parallel action against Mylan proceeded to a bench trial in the N.D. W. Va. that produced a memorandum opinion addressing the '708 and '921 patents (CourtListener recap, gov.uscourts.wvnd.46385.204); I could not confirm the outcome or docket number from the retrieved sources. (3) A design-around pattern worth studying: rather than wait out the salt patent or accept a stay, Zydus developed the sitagliptin free base via 505(b)(2), secured its own patent on a malic-acid-stabilized amorphous form, and got to a non-substitutable branded launch — a route other innovators' challengers now study, and one that complicates "generic entry" analyses of the sitagliptin market. (4) Market and industry context: Januvia/Janumet are multi-billion-dollar DPP-4 franchises (the sitagliptin market was estimated near $10 billion by IQVIA in 2023), and Merck has stated that, as a result of the '708 rulings and settlements, it expects Januvia and Janumet to retain U.S. market exclusivity until May 2026 and Janumet XR until July 2026, notwithstanding Zydus's approved alternative form.

Sourcing notes / limits. Grounded in: JPML MDL 2902 transfer order (jpml.uscourts.gov); D. Del. docket entries for 1:19-cv-00314 (D.I. 1–14); Judge Andrews' consolidated Markman opinion (Nov. 17, 2020, D.I. 135 in 19-cv-00311); PTAB IPR2020-00040 FWD and associated papers; FDA NDA 211566 administrative correspondence and summary review; Drugs@FDA NDA 211566; Merck 10-K/10-Q risk disclosures; JPML/docket reporting sites for the docket list. Not independently verified: the exact docket entry effecting dismissal of 1:19-cv-00314; outcomes of the 2020 follow-on IPRs; and the disposition of the N.D. W. Va. bench trial. No counsel attribution beyond docket listings (Merck: Williams & Connolly and McCarter & English; Zydus: Phillips, McLaughlin & Hall, P.A. with pro hac vice counsel) should be treated as complete or current.

I'll research the docket, MDL, and IPR threads for this case.

Key finds so far. Let me dig into the Zydus-specific docket entries, the 505(b)(2) case, and settlement timing.

I'll research the counsel of record for Merck in this action using targeted searches.

Good initial hits. Let me pin down the actual docket entries and the pro hac vice orders.

Let me pull the actual docket sheet for the case and confirm pro hac vice entries.

Counsel of Record for Plaintiff Merck Sharp & Dohme Corp. — No. 1:19-cv-00314-RGA

Bottom line: Merck was represented by a two-firm team — **Williams & Connolly LLP

I'll research the docket and counsel for the Zydus defendants in this case.

Let me pull the actual docket and verify each attorney's firm and role.

Defense-side counsel of record — Merck Sharp & Dohme Corp. v. Zydus Pharmaceuticals (USA) Inc., No. 1:19-cv-00314-RGA

Zydus used a two-tier structure typical of Delaware Hatch-Waxman defense: a Wilmington local-counsel firm handling the docket and a Chicago-based national Hatch-Waxman team admitted pro hac vice. Appearances in this docket were entered in February–March 2019.

Docket anchors (D. Del. 1:19-cv-00314-RGA): D.I. 10 (Bilson Notice of Appearance, 3/8/2019); D.I. 14 (Motion for Pro Hac Vice Appearance of Gaertner, Abramowitz, Blessing and Cassella, filed by Bilson, 3/19/2019, with individual certifications); order granting PHV signed by Judge Andrews 3/19/2019; PHV attorneys added to electronic noticing 3/21/2019. The same six-person structure appears on the MDL 2902 docket (1:19-md-02902-RGA), where Phillips is designated LEAD ATTORNEY for Zydus and Blessing, Cassella, Abramowitz and Gaertner appear as PRO HAC VICE.

Cross-reference note. This lineup is mirrored in the related but distinct Zydus thread — Merck Sharp & Dohme Corp. v. Zydus Worldwide DMCC et al., 1:21-cv-00315-RGA (the 505(b)(2) NDA case flagged in the case overview) — where the same PHV motion (Gaertner, Abramowitz, Blessing, Cassella) was filed via Bilson and granted by Judge Andrews on 4/19/2021. That confirms the same defense team ran both Zydus matters.

Limits / caveats.

• No in-house counsel for Zydus or Cadila appears on the public docket; the publicly available record shows only outside counsel.
• The Justia/CourtListener docket text I retrieved was last captured March 21, 2019. Because the case stayed open until the December 2022 settlement, later appearances, substitutions, or withdrawals (plausible given the Locke Lord → Buchanan Ingersoll move) may exist on the full PACER docket and are not reflected above. Treat the roster as accurate for the 2019–2021 litigation window rather than as a certified end-of-case list.
• Firm affiliations are stated as of the relevant filings; I have flagged the two confirmed later moves (Gaertner and Abramowitz to Buchanan Ingersoll & Rooney; Cassella to Goodwin) and expressly note that Blessing's post-Locke Lord affiliation is unverified.